*** ALL THINGS MONEY >>>> ATM ***

[EZ2]

Cha~Ching $$$$$$$$$$$$$


Bristol-Myers to acquire Celgene in cash-and-stock deal with equity value of about $74 billion

MARKETWATCH 7:08 AM ET 1/3/2019

Symbol Last Price Change
BMY 52.43up +0 (+0%)
CELG 66.64up 0 (0%)
QUOTES AS OF 04:01:28 PM ET 01/02/2019

Bristol Myers-Squibb Co. (BMY) and Celgene Corp.(CELG) said Thursday they have agreed to merge in a deal in which Bristol-Myers will acquire Celgene(CELG) for cash and stock with an equity value of about $74 billion. Under the terms of the deal, Celgene(CELG) shareholders will receive 1.0 Bristol-Myers share and $50 in cash for each share of Celgene(CELG). They will also receive one tradeable Contingent Value Right for each share owned, which will entitle them to a payment for the achievement of certain future regulatory milestones. Based on Bristol-Myers closing price on Jan. 2, the deal is worth $ 102.43 per Celgene(CELG) share and one CVR. Bristol-Myers shareholders will own about 69% of the combined company when the deal closes, which is expected in the third quarter of 2019. Bristol-Myers is expecting to achieve run-rate cost synergies of about $2.5 billion by 2022. The deal is expected to immediately boost per-share earnings. Celgene(CELG) shares surged 33% in premarket trade, while Bristol-Myers shares fell 10.3%. S&P 500 futures were down 42 points.

-Ciara Linnane; 415-439-6400; [e-mail]


(END) Dow Jones Newswires
01-03-190708ET
Copyright (c) 2019 Dow Jones & Company, Inc.